HUMORAL AND CELLULAR IMMUNE RESPONSES TO TUMOR ASSOCIATED ANTIGENS (TAA) PATIENT
HUMORAL AND CELLULAR IMMUNE RESPONSES TO TUMOR ASSOCIATED ANTIGENS (TAA) PATIENT
批准号:
8356782
负责人:
Stephen Gottschalk
金额:
$0.08万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2011-11-30
关键词:
AdultBrain NeoplasmsCancer CenterCancer EtiologyChildClinical ResearchDevelopmentDiseaseEndocrineFaceFundingGrantImmune responseImmunotherapeutic agentMalignant GliomaMalignant NeoplasmsNational Center for Research ResourcesPatientsPrincipal InvestigatorResearchResearch InfrastructureResourcesSecond Primary CancersSourceTexasTumor AntigensUnited States National Institutes of Healthcosthearing impairmentinnovationmortalityneuropsychologicalnovelprogramstreatment strategy
中文摘要
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
脑瘤是儿童癌症死亡的主要原因,也是成人癌症死亡的重要原因。尽管在治疗其他类型的恶性肿瘤方面取得了重大进展,但治疗脑瘤的进展却缓慢得令人痛苦。此外,那些幸存下来的患者经常面临来自他们的疾病和治疗方法的重大长期并发症。这些并发症可能包括神经心理和智力功能的进行性下降,继发性恶性肿瘤的发展,神经内分泌异常和永久性听力损失。德克萨斯州儿童癌症中心(TCCC)的脑瘤研究计划专注于寻找比现有治疗方法更有效、毒性更低的脑瘤新治疗方法。在这项提案中,我们寻求对一个新项目的支持,该项目旨在为所有脑肿瘤中最具破坏性的恶性胶质瘤开发一种创新的免疫治疗策略。
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Brain tumors are the leading cause of mortality in children with cancer and are a significant cause of cancer mortality in adults as well. Despite significant advances in the treatment of other types of malignancies, progress in treating brain tumors has been painfully slow. Moreover, those patients who do survive frequently face major, long-term complications from their disease and the therapies used to treat them. These complications may include progressive decline in neuropsychological and intellectual functioning, the development of secondary malignancies, neuro-endocrine abnormalities, and permanent hearing loss. The Texas Childrens Cancer Centers (TCCC) brain tumor research programs is focused on identifying new treatment approaches for brain tumors that are more effective and less toxic than currently available treatments. In this proposal we seek support for a novel project aimed at developing an innovative immunotherapeutic treatment strategy for the most devastating of all brain tumors known as malignant gliomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy
-
批准号:10672305
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2022
-
负责人:Stephen Gottschalk
-
依托单位:
Reprogramming of T cells for the Treatment of Melanoma
-
批准号:8545127
-
项目类别:
-
资助金额:$96.58万
-
财政年份:2012
-
负责人:Stephen Gottschalk
-
依托单位:
Reprogramming of T cells for the Treatment of Melanoma
-
批准号:8412064
-
项目类别:
-
资助金额:$101.44万
-
财政年份:2012
-
负责人:Stephen Gottschalk
-
依托单位:
Reprogramming of T cells for the Treatment of Melanoma
-
批准号:8708792
-
项目类别:
-
资助金额:$99.57万
-
财政年份:2012
-
负责人:Stephen Gottschalk
-
依托单位:
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
-
批准号:8513789
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2011
-
负责人:Stephen Gottschalk
-
依托单位:
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
-
批准号:8322026
-
项目类别:
-
资助金额:$32.98万
-
财政年份:2011
-
负责人:Stephen Gottschalk
-
依托单位:
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
-
批准号:8037937
-
项目类别:
-
资助金额:$33.54万
-
财政年份:2011
-
负责人:Stephen Gottschalk
-
依托单位:
ADMINISTRATION OF HER2 CHIMERIC RECEPTOR AND TGFBETA DOMINANT NEGATIVE RECEPTOR
-
批准号:8356777
-
项目类别:
-
资助金额:$1.07万
-
财政年份:2010
-
负责人:Stephen Gottschalk
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTATOXIC T-LYMPHOCYTE
-
批准号:8356771
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2010
-
负责人:Stephen Gottschalk
-
依托单位:
ADMINISTRATION OF HER2 CHIMERIC RECEPTOR AND TGFBETA DOMINANT NEGATIVE RECEPTOR
-
批准号:8166774
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2009
-
负责人:Stephen Gottschalk
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTATOXIC T-LYMPHOCYTE
-
批准号:8166767
-
项目类别:
-
资助金额:$5.44万
-
财政年份:2009
-
负责人:Stephen Gottschalk
-
依托单位:
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTE
-
批准号:7950692
-
项目类别:
-
资助金额:$5.16万
-
财政年份:2008
-
负责人:Stephen Gottschalk
-
依托单位:
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas
-
批准号:7253725
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2007
-
负责人:Stephen Gottschalk
-
依托单位:
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER
-
批准号:8182186
-
项目类别:
-
资助金额:$26.93万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER
-
批准号:8182179
-
项目类别:
-
资助金额:$26.49万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER
-
批准号:8378617
-
项目类别:
-
资助金额:$25.92万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER
-
批准号:8217343
-
项目类别:
-
资助金额:$26.03万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER
-
批准号:7407205
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
Improving T Cell Therapies for Nasopharyngeal Cancer
-
批准号:8435589
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2002
-
负责人:Stephen Gottschalk
-
依托单位:
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency
-
批准号:10207734
-
项目类别:
-
资助金额:$57.62万
-
财政年份:1997
-
负责人:Stephen Gottschalk
-
依托单位:
海外基金